-
October - December 2023 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
04 Feb 2024 08:45 GMT
… that contribute to wrong drug errors
FDA is evaluating the need …
Braftovi (encorafenib)
Zelboraf (vemurafenib)
Haemophagocytic lymphohistiocytosis
FDA is evaluating the need … and simvastatin)
Zetia (ezetimibe)
Drug-induced liver injury
The “Postmarketing …
-
What to know about melanoma medication
18 Dec 2023 16:22 GMT
… encorafenib (Braftovi), vemurafenib (Zelboraf), and dabrafenib (Tafinlar), … They come in pill form and include … to other treatments.
Chemotherapy drugs for melanoma … therapy drugs, immunotherapy medications, and chemotherapy drugs.
However, doctors typically …
-
Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma
10 Aug 2023 17:19 GMT
… the targeted therapies vemurafenib (Zelboraf) and cobimetinib (Cotellic) … added treatments.
In the early-phase trial, treatment with both drugs … New England Journal of Medicine.
Study participants all … an NCI-sponsored clinical trials group, to search for …
-
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
08 May 2023 20:02 GMT
… and in other combination treatment strategies.
The company … ZELBORAF® in China. Wei obtained his M.D. at Harvard Medical … commercial experience across biotech and pharmaceutical companies, Alicia … preclinical and clinical trials, the regulatory approval …
-
Remix Therapeutics Appoints Christopher Bowden, M.D., as Chief Medical Officer
06 Jan 2023 06:51 GMT
… Therapeutics (Remix), a biotechnology company developing small molecule … novel targeted oncology medicines, including Zelboraf™ for patients with … Pharmacia Corporation and Janssen Pharmaceutical, Inc. Prior to … industry and cooperative group trials.
Dr. Bowden …
-
FDA approves cobimetinib for histiocytic neoplasms
03 Nov 2022 13:03 GMT
… single-institution phase 2 trial of single-agent cobimetinib … result of research and trials conducted at [Memorial Sloan … principal investigator of the trial said in a press … The FDA previously approved vemurafenib (Zelboraf, Genentech) for treatment of Erdheim …
-
FDA Approves Oral MEK Inhibitor Cobimetinib for Histiocytic Neoplasms, Research Led by Memorial Sloan Kettering Cancer Center
02 Nov 2022 03:22 GMT
… FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment … of vemurafenib (Zelboraf®) in 2017 for the treatment of Erdheim- … result of research and trials conducted at MSK, and … poor long-term tolerance. Doctors at MSK care for …
-
Global precision medicine market is projected to grow at a CAGR of 10.8% by 2032: Visiongain Reports Ltd
13 Oct 2022 10:00 GMT
… drug development has been the core objective of pharmacological, pharmaceutical … commercially known as “Zelboraf”, and Merck has … changing circumstances. Precision medicine treatments can help to … Over the decade, biotechnology has progressed immensely. …
-
Malignant Melanoma Treatment Market is Valued at USD 7.68 Billion at a Potential Growth rate of 11.74% By 2028
09 Sep 2022 09:53 GMT
… late phase in drug trials and approval by … cotellic, zelboraf, imlygic and generic drugs.
Global Malignant Melanoma Treatment Market … , Merck KGaA, ONO PHARMACEUTICAL CO. LTD., DAIICHI SANKYO … /global-portable-medical-electronic-devices-market
https …
-
Global precision medicine market is projected to grow at a CAGR of 10.8% by 2032: Visiongain Reports Ltd
21 Jul 2022 08:38 GMT
… drug development has been the core objective of pharmacological, pharmaceutical … commercially known as “Zelboraf”, and Merck has … changing circumstances. Precision medicine treatments can help to … Over the decade, biotechnology has progressed immensely. …